Merck Healthcare today announced a licensing agreement with Inspirna, Inc. for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds. Ompenaclid is currently being evaluated in a Phase II study for the second-line…
AbbVie and Umoja Biopharma, an early clinical-stage biotechnology company, today announced two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using Umoja’s proprietary VivoVecTM platform. The first agreement provides AbbVie an exclusive…
Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). The partnership brings together Ribo’s leading experience in the discovery and clinical development of…
Voyager Therapeutics, a biotech company dedicated to advancing neurogenetic medicines, announced a strategic collaboration and capsid license agreement with Novartis Pharma, a subsidiary of Novartis to advance potential gene therapies for Huntington’s disease and spinal muscular atrophy. Voyager will provide…
Roche announced the entry into a definitive agreement to acquire select parts of the LumiraDx group related to LumiraDx’s innovative Point of Care technology. Following closing of the transaction, which is expected by mid-2024, the acquired entities will be fully…
AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, furthering the AstraZeneca cell therapy ambition. The proposed acquisition will enrich AstraZeneca’s…
Bristol Myers Squibb and RayzeBio announced a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash…
Chiesi Group, has been awarded the 59th Oscar di Bilancio for the Benefit Corporation category, sponsored by Federazione Relazioni Pubbliche Italiana, Borsa Italiana and Università Bocconi. The award ceremony entitled “Shared Value – The Future of Reporting is Written Today”…
Bristol Myers Squibb and Karuna Therapeutics announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna for a total equity value of $14.0 billion, or $12.7 billion net of estimated…
GSK and Hansoh Pharma, a Chinese biopharmaceutical company committed to discovering and developing life-changing medicines to help patients conquer serious diseases and disorders, today announced that they have entered into an exclusive license agreement for HS-20093, a B7-H3 targeted antibody-drug…